Pfizer Stops Enrollment in COVID-19 Pill Trial After Latest Results

Pfizer Stops Enrollment in COVID-19 Pill Trial After Latest Results
Paxlovid, a Pfizer COVID-19 pill, is seen manufactured in Ascoli, Italy, in this undated photo obtained by Reuters on Nov. 16, 2021. Pfizer/Handout via Reuters
Updated:
0:00

Pfizer has announced it will stop enrollment in a clinical trial for Paxlovid—its COVID-19 antiviral pill—for standard-risk COVID-19 patients after the latest results suggested the drug did not reduce symptoms or hospitalizations and deaths to a statistically significant degree.

Paxlovid, which consists of two different antiviral drugs—nirmatrelvir and ritonavir—is currently approved or authorized for conditional or emergency use in more than 65 countries, including the United States, to treat COVID-19 patients at high risk of severe illness, including hospitalization or death.
Related Topics